IMEVAX
ImevaX is a biopharmaceutical company founded in 2014 based in Munich, Germany. The focus is to combat chronic and nosocomial infections by creating specific vaccines. The company’s lead candidate IMX 101 is a vaccine against Helicobacter pylori, which colonizes the stomach and is the cause of ulcer disease and gastric cancer in humans. Founder Markus Gerhard and his team discovered that the colonization ability (and hence, the infectiousness) of H. pylori depends on a secreted bacterial factor that down-regulates the host immune system. Many other highly infectious pathogens have evolved similar immune evasion mechanisms, which are the focus of the ImevaX screening program.
IMEVAX
Industry:
Biotechnology Health Care Medical
Founded:
2014-01-01
Address:
Munich, Bayern, Germany
Country:
Germany
Website Url:
http://www.imevax.com
Total Employee:
11+
Status:
Active
Contact:
(498) 941-4245
Email Addresses:
[email protected]
Total Funding:
17.3 M USD
Technology used in webpage:
Viewport Meta SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Euro Microsoft Exchange Online Organization Schema Office 365 Mail
Current Employees Featured
Founder
Investors List
Santo Venture Capital
Santo Venture Capital investment in Series A - ImevaX
EMBL Ventures
EMBL Ventures investment in Series A - ImevaX
BioMedPartners
BioMedPartners investment in Series A - ImevaX
Wellington Partners
Wellington Partners investment in Series A - ImevaX
German Federal Ministry of Education and Research (BMBF)
German Federal Ministry of Education and Research (BMBF) investment in Grant - ImevaX
Official Site Inspections
http://www.imevax.com Semrush global rank: 5.35 M Semrush visits lastest month: 1.56 K
- Host name: www238.your-server.de
- IP address: 188.40.28.18
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
